TMU’s Spin-off DeepRad.AI – The First AI-driven Pulmonary-Coronary Screening Platform Certified by TFDA

The company has developed an AI-driven pulmonary-coronary screening platform, DeepLung-CAC, which employs a single low-dose computed tomography (LDCT) scan to detect both pulmonary nodules and coronary artery calcification risk. Certified by the Taiwan Food and Drug Administration (TFDA), it is the first domestically developed AI pulmonary-coronary screening platform.

LungRads (Lung Nodule Detection) module comprises lung nodule detection, segmentation, and classification models, trained on a dataset of over 6,000 CT cases. Empowered with advanced 3D deep learning techniques, the module can rapidly detect and analyze lung nodules in less than a minute.

Professor Chen stressed the importance of early detection in increasing lung cancer survival rates. Unlike traditional lung cancer screenings that require 25 to 30 minutes for interpretation, the DeepLung-CAC platform enables radiologists to read LDCT scans in just 5 minutes. Moreover, the platform can conduct multiple disease risk assessments based on a single image.

In addition to DeepLung-CAC, DeepRad.AI has developed DeepBrain-Cognito, a dementia screening platform computational model, which provides personalized assessments of cognitive decline for populations with suboptimal health status.

In 2024, DeepRad.AI was honored with several awards, including the Future Tech Award, NBRP Pitch Day Outstanding Team Award, the GenAI Stars Quality Innovation Award, and the National Pharmaceutical Technology & Research Development Award.